Sandoz 2nd Biosimilar At FDA; Seeks Slice Of Enbrel Sales
This article was originally published in Scrip
With the FDA's acceptance of its 351(k) application, Novartis unit Sandoz has moved closer to gaining the agency's approval to market a second biosimilar – this time, a version of Amgen's tumor necrosis factor alpha (TNF-alpha) inhibitor Enbrel (etanercept), which reported $9bn in global sales in 2014, with close to half of that coming from the U.S.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.